|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquired
|
gptkb:Sanofi
|
|
gptkbp:acquisition
|
gptkb:2011
|
|
gptkbp:awards
|
various industry awards
|
|
gptkbp:ceo
|
gptkb:David_Meeker
|
|
gptkbp:clinical_trial
|
ongoing
completed
phases I, II, III
|
|
gptkbp:community_involvement
|
patient advocacy
education programs
healthcare initiatives
|
|
gptkbp:employees
|
over 10,000
|
|
gptkbp:financial_products
|
investor relations
publicly traded
annual reports available
|
|
gptkbp:focus
|
gptkb:psychologist
genetic disorders
rare diseases
kidney diseases
orthopedic diseases
|
|
gptkbp:founded
|
gptkb:1981
|
|
gptkbp:headquarters
|
gptkb:Cambridge,_Massachusetts
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Genzyme Sanofi
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:innovation
|
drug development
biotechnology advancements
patient-centered solutions
|
|
gptkbp:location
|
gptkb:United_States
|
|
gptkbp:market
|
gptkb:Europe
gptkb:Asia
gptkb:Latin_America
gptkb:North_America
global
|
|
gptkbp:parent_company
|
gptkb:Sanofi
|
|
gptkbp:part_of
|
gptkb:Sanofi_Group
|
|
gptkbp:partnerships
|
various academic institutions
other pharmaceutical companies
|
|
gptkbp:products
|
gptkb:Cerezyme
gptkb:Lemtrada
gptkb:Myozyme
gptkb:Synvisc
gptkb:Thyrogen
|
|
gptkbp:research_and_development
|
biologics
therapeutics
|
|
gptkbp:revenue
|
$4.5 billion (2019)
|
|
gptkbp:subsidiary
|
gptkb:Sanofi
|
|
gptkbp:sustainability
|
environmental initiatives
corporate social responsibility
ethical practices
|
|
gptkbp:symbol
|
SNY
|
|
gptkbp:type
|
gptkb:Company
|
|
gptkbp:website
|
www.genzyme.com
|
|
gptkbp:bfsParent
|
gptkb:Sanofi_Genzyme
|
|
gptkbp:bfsLayer
|
4
|